Results 221 to 230 of about 2,986,953 (305)

Preparation of Rare-Earth-Based Metal–Organic Frameworks and Their PMS Photocatalytic Activation for Rhodamine B Degradation

ACS Omega
Jiaqi Li, Shuai Zhang, Pengyao Sun, Jianfei Li, Tiantian Sun, Renquan Guan, Fanming Zeng, Chunbo Liu   +7 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Inducible and reversible <i>in vivo</i> protein degradation reveals T cell-intrinsic regulatory function of SHP-1. [PDF]

Front Immunol
Khan TH, Ravichandran KS, Lorenz UM.
europepmc   +1 more source

Investigation of Complement Activation and Cytokine Signatures in AQP4+ NMOSD, MOGAD, and MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Aquaporin‐4‐IgG seropositive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), and multiple sclerosis (MS) are pathophysiologically distinct neuroinflammatory disorders. Complement activation is a major mechanism of injury in AQP4+ NMOSD, whereas its role in
Angeliki G. Filippatou, Susana Dominguez‐Penuela, David Acero‐Garces, Georgios Gakis, Matthew D. Smith, Yasmin Resto, Maria Reyes‐Mantilla, Haiwen Chen, Isabella Hernandez, Yana Said, Andrea Salazar‐Camelo, Christina Huynh, Alessia Tassoni, Ted Yednock, Rick Artis, Yaisa Andrews‐Zwilling, Scott D. Newsome, Shiv Saidha, Pavan Bhargava, Ellen M. Mowry, Kathryn C. Fitzgerald, Peter A. Calabresi, Carlos A. Pardo, Elias S. Sotirchos   +23 more
wiley   +1 more source

Development of new ruthenium complex-based photocatalysts for the degradation of Remazol Red Ultra RGB. [PDF]

RSC Adv
de Oliveira DC, de L Souza DT, C Cavalcanti WE, de O Soares J, de L Pontes D, de B Pontes ACF, de F Paulo T, Pergher SBC, da Silva EFON.   +8 more
europepmc   +1 more source

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham, Casey Vanderlip, Colin Birkenbihl, Eashwar Krishna, Chizobam Ugboaja, Andrew E. Budson, Brandon Frank, for the Alzheimer's Disease Neuroimaging Initiative   +7 more
wiley   +1 more source

Targeted protein degradation in cancer: strategies for undruggable targets and progress towards clinical translation. [PDF]

Biomark Res
Tang J, Cheng Z, Xie T, Zhuang Y, Hu H, Li C, Wang H, Feng C, Tu C.   +8 more
europepmc   +1 more source

Generative Artificial Intelligence in Clinical Practice: How Should Rheumatologists Evaluate and Monitor Emerging Tools?

Arthritis Care &Research, EarlyView.
Generative artificial intelligence (AI) is increasingly being used in rheumatology practice, to assist with tasks such as documentation, record summarization, and clinical decision support. Rheumatologists need a practical approach to determining what evidence and oversight each application requires.
Koushan Kouranloo, Mrinalini Dey, Jinoos Yazdany   +2 more
wiley   +1 more source

Post-Translational Regulation and Ubiquitination of Brassinosteroid Signaling Components in Plants. [PDF]

Cells
Jia Q, Du X, Wang T, Gao Z, Dong H, An R, Ji Y, Wei S, Zhang Y, Huang S.   +9 more
europepmc   +1 more source